DE69938871D1 - Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen - Google Patents

Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen

Info

Publication number
DE69938871D1
DE69938871D1 DE69938871T DE69938871T DE69938871D1 DE 69938871 D1 DE69938871 D1 DE 69938871D1 DE 69938871 T DE69938871 T DE 69938871T DE 69938871 T DE69938871 T DE 69938871T DE 69938871 D1 DE69938871 D1 DE 69938871D1
Authority
DE
Germany
Prior art keywords
ctla
self antigens
stimulating
against self
cells against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69938871T
Other languages
English (en)
Inventor
James P Allison
Arthur A Hurwitz
Andrea Vanelsas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69938871D1 publication Critical patent/DE69938871D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
DE69938871T 1998-12-03 1999-12-03 Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen Expired - Lifetime DE69938871D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11076198P 1998-12-03 1998-12-03
PCT/US1999/028739 WO2000032231A1 (en) 1998-12-03 1999-12-03 Stimulation of t cells against self antigens using ctla-4 blocking agents

Publications (1)

Publication Number Publication Date
DE69938871D1 true DE69938871D1 (de) 2008-07-17

Family

ID=22334796

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69938871T Expired - Lifetime DE69938871D1 (de) 1998-12-03 1999-12-03 Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen

Country Status (11)

Country Link
EP (1) EP1137436B1 (de)
JP (1) JP5341287B2 (de)
AT (1) ATE397457T1 (de)
AU (1) AU774962B2 (de)
CA (1) CA2352783C (de)
CY (1) CY1108318T1 (de)
DE (1) DE69938871D1 (de)
DK (1) DK1137436T3 (de)
ES (1) ES2308857T3 (de)
PT (1) PT1137436E (de)
WO (1) WO2000032231A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
CN1240436C (zh) * 2002-08-28 2006-02-08 上海益众生物技术有限公司 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用
WO2004081021A2 (en) * 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
ES2608316T3 (es) 2005-06-08 2017-04-07 Dana-Farber Cancer Institute, Inc. Métodos y composiciones para el tratamiento del cáncer e infecciones persistentes mediante la inhibición de la ruta de la muerte celular 1 (PD-1) programada
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
JP5960597B2 (ja) 2009-09-30 2016-08-02 メモリアル スローン−ケタリング キャンサー センター 癌治療のための併用免疫療法
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
CN104284674A (zh) * 2012-05-04 2015-01-14 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
CN111167008A (zh) 2013-12-05 2020-05-19 免疫系统公司 利用射频电学膜击穿（rf-emb）的癌症免疫疗法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
KR20230164243A (ko) 2015-03-23 2023-12-01 조운스 테라퓨틱스, 인크. Icos에 대한 항체
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2017070423A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP2019503398A (ja) * 2016-01-15 2019-02-07 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー がんの免疫学的処置
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
US20190382490A1 (en) 2017-02-28 2019-12-19 Bristol-Myers Squibb Company Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781596A1 (de) 2018-04-18 2021-02-24 Xencor, Inc. Il-15/il-15ra-heterodimere fc-fusionsproteine und verwendungen davon
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
EP3861016A2 (de) 2018-10-03 2021-08-11 Xencor, Inc. Il-12-heterodimere fc-fusionsproteine
KR20210091710A (ko) 2018-10-12 2021-07-22 젠코어 인코포레이티드 PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP7405361B2 (ja) 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
JP2021120355A (ja) 2020-01-30 2021-08-19 東亞合成株式会社 Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) * 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用

Also Published As

Publication number Publication date
EP1137436B1 (de) 2008-06-04
WO2000032231A1 (en) 2000-06-08
ATE397457T1 (de) 2008-06-15
EP1137436A1 (de) 2001-10-04
DK1137436T3 (da) 2008-10-13
JP5341287B2 (ja) 2013-11-13
JP2002531416A (ja) 2002-09-24
CA2352783A1 (en) 2000-06-08
CY1108318T1 (el) 2014-02-12
PT1137436E (pt) 2008-09-15
ES2308857T3 (es) 2008-12-01
CA2352783C (en) 2012-04-10
AU2164900A (en) 2000-06-19
AU774962B2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
DE69938871D1 (de) Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
SE9700182D0 (sv) Implantable heart stimulator
DE59611341D1 (de) Verwendung von saccharid-konjugaten
CY1106046T1 (el) Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης
ATE239474T1 (de) Verwendung von levobupivacain
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
DE69621243D1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
DK0855916T3 (da) Farmaceutisk præparat indeholdende en Activin-stimulator
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
IL131478A0 (en) Methods for treatment of scar tissue
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
TR200000090T2 (tr) Serotonin'in seçici olarak yeniden yapıya alınma inhibitörleri (SSRI) kullanılarak kalp hastalıklarının tedavisi ve önlenmesi.
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
PT958290E (pt) Derivados de 1,4-di-hidropiridina e seu uso em terapia
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин

Legal Events

Date Code Title Description
8364 No opposition during term of opposition